Schvarcz R, von Sydow M, Weiland O
Dept. of Infectious Diseases, Karolinska Institute, Stockholm, Sweden.
Scand J Gastroenterol. 1990 Nov;25(11):1175-80. doi: 10.3109/00365529008998551.
Thirty-three patients fulfilling stringent criteria for autoimmune chronic active hepatitis (CAH) were tested for antibodies against hepatitis C virus (anti-HCV) with an enzyme immunoassay. Eleven of the 33 (33%) patients were anti-HCV-reactive in a serum drawn before initiation of immunosuppressive therapy. Anti-HCV-reactive patients had significantly higher median s-IgG level (32.3 g/l) than nonreactive patients (23.5 g/l) (p less than 0.01). When in remission with normalized s-IgG levels as a result of the immunosuppressive therapy, only 1 of the 11 initially reactive patients was still reactive. Sera from patients with acute autoimmune CAH and high s-IgG levels may be nonspecifically reactive for anti-HCV.
对33例符合自身免疫性慢性活动性肝炎（CAH）严格标准的患者，采用酶免疫分析法检测其抗丙型肝炎病毒抗体（抗-HCV）。33例患者中有11例（33%）在开始免疫抑制治疗前抽取的血清中抗-HCV呈反应性。抗-HCV反应性患者的中位s-IgG水平（32.3 g/l）显著高于无反应性患者（23.5 g/l）（p<0.01）。由于免疫抑制治疗，当s-IgG水平恢复正常且病情缓解时，最初11例反应性患者中只有1例仍呈反应性。急性自身免疫性CAH且s-IgG水平高的患者血清可能对抗-HCV呈非特异性反应。
